Skip to main content

Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain


Start Date
End Date
Total Funding
€ 17 410 136
Funding Programme

The overall aim is to further the understanding of the BBB in health and disease states towards the development of innovative brain delivery systems, especially for biopharmaceuticals (e.g., peptides, antibodies, etc.) and the identification of novel disease drug targets (Alzheimer’s Disease, MS, metabolic disease).

The related key deliverables will be as follows:

1.Identification and validation of specific genes and/or mechanisms which are altered in brain endothelial cells in disease.

2. Generation, validation and characterisation of robust and predictive iPSC-derived BBB models: The developed models should be more reflective of the in vivo situation than existing models, in the healthy and disease states.

3. New, efficacious and safe mechanisms and technologies of brain delivery: The output of this topic should also result in an expanded and deepened understanding of the fundamental processes that underpin drug-trafficking across the BBB, which in turn can further support endeavours to elucidate novel and more efficacious brain delivery mechanisms.

4. Characterised new genetic models for the diseases of interest in this topic which are better amenable to evaluate disease-modifying agents.

5. Characterised mechanisms of neurotropic virus-mediated BBB and CNS penetration for development of selective brain delivery systems.

6. Established in silico/mathematical models in predicting BBB penetration of therapeutics (such as receptor-or carrier-mediated transcytosis for delivery across the BBB) and pharmacokinetics of biopharmaceutics in different compartments of CNS.

7. Identification of relevant translational readouts which are better amenable to elucidate the role of the BBB in the pathogenesis of neurodegeneration and could eventually lead to new targets for the treatment of the neurovascular causes of the diseases.

Project partners

Academisch Ziekenhuis Leiden
Aarhus Universitet
Pfizer Limited
Mimetas Bv
Ait Austrian Institute Of Technology Gmbh
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat
Stiftung Tieraerztliche Hochschule Hannover
The University Of Sheffield
Fujifilm Cellular Dynamics Inc
Novartis Pharma Ag
University Of Dundee
Artemis Bio-Support B.V.
Ruprecht-Karls-Universitaet Heidelberg
Kobenhavns Universitet
Uppsala Universitet
Neuway Pharma Gmbh
Stichting Vumc
H. Lundbeck As
Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz
Sanofi-Aventis Recherche & Developpement
Novo Nordisk A/S
The Open University
Pharmacoidea Fejleszto Es Szolgaltato Kft
Universita Degli Studi Di Modena E Reggio Emilia
Janssen Pharmaceutica Nv
Cardiff University
The Chancellor
Masters And Scholars Of The University Of Oxford

Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).